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Abstract
Background: Given the limited efficacy and high adverse event rate associated with treatment of recurrent hepatitis C after
liver transplantation, an individualized treatment strategy should be considered. The aim of this study was to identify
predictors of response to antiviral therapy for hepatitis C after living donor liver transplantation (LDLT) and to study the
associated adverse events.
Methods: A retrospective chart review was performed on 125 hepatitis C virus (HCV)-positive LDLT recipients who received
interferon plus ribavirin and/or peginterferon plus ribavirin therapy at Kyoto University between January 2001 and June
2011.
Results: Serum HCV RNA reached undetectable levels within 48 weeks in 77 (62%) of 125 patients, and these patients were
defined as showing virological response (VR). Of 117 patients, 50 (43%) achieved sustained VR (SVR). Predictive factors
associated with both VR and SVR by univariate analysis included low pretransplant serum HCV RNA levels, a non-1 HCV
genotype, and low pretreatment serum HCV RNA levels. In addition, LDLT from ABO-mismatched donors was significantly
associated with VR, and white cell and neutrophil counts before interferon therapy were associated with SVR. Multivariate
analysis showed that 2 variables–pretransplant serum HCV RNA level less than 500 kIU/mL and a non-1 HCV genotype–
remained in models of both VR and SVR and that an ABO mismatch was associated with VR. No variables with a significant
effect on treatment withdrawal were found.
Conclusions: Virological response to antiviral therapy in patients with hepatitis C recurring after LDLT can be predicted prior
to transplant, based on pretransplant serum HCV-RNA levels and HCV genotype. LDLT from ABO-mismatched donors may
contribute to more efficacious interferon therapy.
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Introduction
Hepatitis C virus (HCV) infection, leading to liver cirrhosis and
hepatocellular carcinoma, is the leading indications for liver
transplantation in Japan, the United States, and Western Europe.
However, almost all patients who undergo liver transplantation for
HCV-related liver disease develop recurrent viral infection, and
70–90% of patients suffer from histologically proven recurrent
hepatitis [1,2,3,4,5,6]. The progression of recurrent hepatitis C is
often accelerated and, without appropriate antiviral therapy, 10–
25% of patients develop cirrhosis within 5 years after transplan-
tation, resulting in poorer prognoses for HCV-positive recipients
than HCV-negative recipients [7]. To prevent the progression of
hepatitis C after liver transplantation, interferon-based combina-
tion therapy is commonly administered [8,9]. However, its efficacy
in liver transplant recipients is limited, with the mean sustained
virological response (SVR) rate among patients with recurrent
hepatitis C after liver transplantation being only 30% (range, 8–
50%) [10]. One of the reasons for the low SVR rate is the high
rate of treatment withdrawal. Several severe adverse events have
been reported in transplant recipients after interferon therapy,
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including chronic rejection and de novo autoimmune hepatitis
[11,12,13].
To improve the efficacy of anti-HCV treatment in patients with
hepatitis C after liver transplantation, an individualized treatment
strategy based on efficacy prediction and adverse events should be
attempted. In several studies, an analysis of predictors associated
with SVR was conducted in patients with recurrent hepatitis C
after deceased donor liver transplantation (DDLT)
[10,14,15,16,17,18,19,20]. In these studies, variables most fre-
quently associated with SVR were early virological response
(EVR) at 3 months of therapy, HCV genotype 2, adherence to
therapy, and baseline viremia [14,15,16,17,18,19,20]. Of these
factors, EVR and adherence to therapy can only be recognized
after the initiation of treatment. However, to enable decisions on
treatment indications and strategy, predictors of response that are
available before initiation of therapy are more valuable. Thus, an
individualized treatment strategy could be based on the identifi-
cation of baseline predictive factors before interferon therapy.
Moreover, no study of factors predictive of response to the
interferon therapy in patients with recurrent hepatitis C after
living donor liver transplantation (LDLT) has been reported so far.
Characteristics specific to LDLT, including blood-relative donors,
post-transplant liver regeneration, and ABO-incompatible liver
transplantation, might cause the antiviral effects of interferon
therapy in these patients to differ from those who received DDLT.
The direct-acting antiviral agents telaprevir and boceprevir
recently became available for clinical use. The results of clinical
trials of these agents in combination with peginterferon plus
ribavirin in nontransplant patients with HCV were promising
[21,22,23,24]. SVR rates to telaprevir-based combination therapy
were significantly higher than those to the peginterferon-ribavirin
combination. The efficacy in the patients who had suffered a
relapse after a previous treatment by peginterferon plus ribavirin
was especially striking [21,24]. The SVR rate to telaprevir based-
therapy in patients who had a previous relapse was more than
80%, while that in patients who had no response to previous
treatment was around 30% [24]. These results suggest that
patients who show a virological response (VR) to peginterferon
plus ribavirin are expected to achieve SVR after telaprevir-based
therapy. Therefore, identification of factors predictive of virolog-
ical response to peginterferon plus ribavirin should also prove
useful when making the clinical decision about telaprevir usage. In
liver transplant recipients, the use of telaprevir and boceprevir
poses risks because of their inhibitory action on the enzyme
cytochrome P450 3A, responsible for the metabolism of both
tacrolimus and cyclosporine. In fact, the phase I study of telaprevir
in healthy individuals revealed that it significantly increased the
blood concentrations of both tacrolimus and cyclosporine [25].
Therefore, the selection of the patients for whom telaprevir is
prescribed is especially important in liver transplant recipients.
Recently, a polymorphism in the interleukin-28B (IL28B) gene
region, encoding interferon-lambda 3, was identified as a strong
predictive factor for response to antiviral treatment in nontrans-
plant patients with hepatitis C [26,27,28]. In post-transplant
patients, the IL28B polymorphism in both recipients and donors
was shown to be associated with response to antiviral treatment
[29,30]. In addition, HCV-RNA mutations, including those
affecting amino acid (aa) residues 70 and 91 in the core region
of HCV and those in the interferon sensitivity determining region
(ISDR) in nonstructural protein 5A (NS5A), were also demon-
strated to be predictors of response to interferon therapy in
transplant recipients, as well as in nontransplant settings
[31,32,33]. These factors could be used to predict response to
antiviral therapy, but these are presently not part of a routine
clinical examination and require special techniques not covered by
health insurance. Moreover, probing individual genetic informa-
tion poses potential ethical issues.
The aims of this study were, therefore, to identify noninvasively
obtained regular baseline factors associated with VR, SVR, and
treatment withdrawal, in order to elucidate the factors associated
purely with response to interferon therapy, to identify the
valuables related to final outcomes, and to clarify the factors
associated with adverse events.
Methods
A retrospective chart review was performed for all HCV-
positive liver transplant patients who received antiviral therapy
with standard interferon and/or pegylated interferon in combi-
nation with ribavirin after liver transplantation at Kyoto
University between January 2001 and June 2011.
Patients
Between March 1999 and June 2011, 214 HCV-positive
recipients underwent LDLT at Kyoto University. Of these, 157
patients were followed up for more than 6 months after LDLT in
our hospital. Anti-viral therapy was administered to 125 of the 157
patients with recurrent hepatitis C between January 2001 and
June 2011. The remaining 32 patients did not receive anti-viral
therapy for various reasons: serum HCV-RNA negative after
LDLT (n= 4), no histological hepatitis C recurrence in the follow-
up period (n= 13), no fibrosis seen by liver histology (n = 8), and
ongoing treatment for the other complications (n = 7). HCV RNA
concentrations and histological evidence were used to diagnose
patients with recurrent hepatitis C after LDLT. These patients
were given combination therapies with interferon plus ribavirin
and/or peginterferon plus ribavirin at Kyoto University between
January 2001 and June 2011. The study protocol was approved by
the Ethics Committee at Kyoto University and performed in
compliance with the Helsinki Declaration. Written informed
consent for participation in this study was not obtained, because
this study is an observational study without use of human
specimen. Our institutional review board waived the need for
written informed consent from the participants of the initial study.
Treatment Protocol and Definition of Responses to
Treatment
Between January 2001 and April 2004, patients with recurrent
hepatitis C after LDLT received treatment with interferon-a-2b (3
or 6 mega units, 3 times/week) plus ribavirin (400–800 mg/day
orally), for the first 6 months. This was followed by interferon
monotherapy for 6 months [34]. Forty patients received this
treatment. Of the 40 patients, 14 patients achieved SVR and 9
withdrew from the treatment protocol. The remaining 17 patients,
including 2 who relapsed and 15 nonresponders were retreated by
the following protocol with peginterferon and rebavirin. Between
May 2004 and June 2011, patients received combination therapy
with peginterferon-a-2b (1.5 mg/kg) plus ribavirin (400–800 mg/
day orally) [35]. Patients who acquired a negative serum HCV
RNA status within 12 months after treatment initiation continued
to receive the treatment for an additional 12 months before
treatment termination. Total 102 patients, including 17 patients
who had previously treated with standard interferon plus ribavirin
and did not achieve SVR, were treated with this treatment
protocol. Patients who were negative for serum HCV RNA for
more than 6 months after completion of interferon therapy were
defined as having achieved SVR. If serum HCV RNA was positive
after 12 months of treatment, therapy was discontinued or
Predictors of HCV Treatment after LDLT
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switched to maintenance therapy with low-dose peginterferon
[36], and the patient was classified as having shown no response.
Treatment was discontinued in patients with severe adverse events.
Additionally, peginterferon treatment was discontinued when
neutrophil and platelet counts fell below 500/mL and 30000/mL,
respectively, and ribavirin was discontinued when hemoglobin
levels fell below 8 g/dL.
We studied the final outcomes of the treatment with
peginterferon plus ribavirin (n = 102) and with standard interferon
plus ribavirin (n = 23).
Histological Assessment
Liver biopsies were performed when patients’ alanine amino-
transferase (ALT) levels were more than twice the normal upper
limit, or at yearly intervals, with informed consent. Biopsy
specimens were evaluated by 2 pathologists (H.H. and A.M-H.)
with extensive experience in the pathology of liver transplantation.
Necroinflammatory activity (A0–A3) and fibrosis stage (F0–F4)
were assessed using METAVIR scores [37,38]. Activity was
graded as A0 (no activity), A1 (mild activity), A2 (moderate
activity), or A3 (severe activity); Fibrosis was staged as F0 (no
fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe
fibrosis), or F4 (cirrhosis).
Immunosuppression
Tacrolimus and low-dose steroid therapy were administered to
induce immunosuppression in most patients [34]. Four patients
received cyclosporine microemulsions instead of tacrolimus.
Mycophenolate mofetil was administered to patients who experi-
enced refractory rejection or required reduction of tacrolimus or
cyclosporine doses due to adverse events. Patients who received
ABO blood-type incompatible transplants were treated with
rituximab, plasma exchange, and hepatic artery or portal vein
infusion with prostaglandin E1 and methylprednisolone [39].
Virological Assays
HCV genotype was determined using a genotyping system
based on polymerase chain reaction (PCR) to amplify the core
region using genotype-specific PCR primers [40]. Serum HCV
RNA load was evaluated before LDLT, before interferon
treatment, once a month during treatment, and 24 weeks after
treatment, using PCR and an Amplicor HCV assay (Cobas
Amplicor HCV Monitor, Roche Molecular Systems, Pleasanton,
CA, USA) until April 2008, or a real-time PCR-based quantitation
method for HCV (COBAS AmpliPrep/COBAS TaqMan HCV
Test, Roche Molecular Systems, Pleasanton, CA, USA) from May
2008. Detection of amino acid substitutions in the HCV core
region was performed using the method reported previously [31].
Statistical Analysis
To evaluate the association between the patient characteristics
and the outcomes (VR, SVR, or withdrawal), the Wald test was
performed based on a logistic regression model. Multivariate
logistic regression analysis with backward variable selection was
used to identify independent and significant predictors for the
outcomes, and to estimate the odds ratio (OR) ant its 95%
confidence interval (CI). A p-value of 0.05 was used for variable
selection and was regarded as significant. Statistical analyses were
performed using SAS version 9.2 (SAS Institute Inc., Cary NC).
Results
Patient Characteristics
This study included 125 HCV-infected liver transplant patients
treated with standard interferon and/or pegylated interferon in
combination with ribavirin for recurrent hepatitis C after LDLT.
Of the 125 patients, 69 (55%) were male, and the median age was
57 years (range: 15–70) at the beginning of the therapy. Most
patients were infected with HCV genotype 1b (n= 103, 82%).
HCV genotypes of the remaining patients were 2a (n= 13), 2b
(n= 5), 3a plus 3b (n= 1), not determined (n= 2), and not
examined (n= 1). Median serum HCV RNA load was 410 kIU/
mL (range: ,0.5–5000,kIU/mL) before LDLT, and 3260 kIU/
mL (range: 31–69000,kIU/mL) at the beginning of the interferon
therapy after LDLT. The median donor age was 41 (range: 19–65)
years. Seventy-two donors (58%) were male, and 86 (69%) were
related to the recipients. The graft type was the right lobe in 109
patients (87%), and the left lobe in 16 patients (13%). The blood
type combination was incompatible in 26 patients (21%). The
median time to treatment initiation after LDLT was 9.0 months
(1.1–85.3 months). Before treatment, the necroinflammatory
activity was A1 or greater in all patients, and 104 patients (83%)
had a fibrosis score of F1 or greater (METAVIR score).
Tacrolimus-based immunosuppression was used in 116 patients
(93%). Among patients receiving tacrolimus for immunosuppres-
sion, the mean serum trough level was 6.0 ng/mL (range: 2.0–
12.7) at the initiation of interferon therapy. In addition to
calcineurin inhibitors, mycophenolate mofetil and prednisolone
were used at the initiation of the interferon treatment in 36 (29%)
and 19 (15%) patients, respectively.
Efficacy of Interferon Therapy
Of the 125 patients who received interferon therapy, serum
HCV RNA reached undetectable levels (less than 0.05 kIU/mL)
within 48 weeks in 77 patients (62%) (Figure 1). These patients
were defined as showing virological response (VR). Of the
remaining 48 patients, 2 patients received treatment for less than
48 weeks, and 15 patients withdrew from the treatment protocol
within 48 weeks because of worsening of liver function (n= 5),
recurrent hepatocellular carcinoma (n= 2), ascites (n = 2), anemia
(n = 1), leucopenia (n = 1), brain hemorrhage (n = 1), biliary
complication (n= 1), sepsis (n = 1), or myocardial infarction
(n= 1). The remaining 31 patients with detectable HCV RNA in
the serum 48 weeks after the initiation of the treatment were
placed in the non-VR group. All patients in the non-VR group
received peginterferon plus ribavirin therapy, including 9 patients
who had previously treated with standard interferon plus ribavirin
and did not achieve SVR. Of the patients with VR, 11
discontinued the treatment protocol within 24 weeks after serum
HCV-RNA became negative, and 6 patients are still under
treatment. The reasons for discontinuation were biliary compli-
cations (n = 2), worsening of liver function (n= 2), general fatigue
(n = 2), recurrent hepatocellular carcinoma (n = 1), leucopenia
(n = 1), hemoptysis (n = 1), brain tumor (n= 1), and depression
(n= 1). Of 60 patients who achieved VR and completed the
treatment protocol, 50 achieved SVR and 10 relapsed. None of
the non-VR patients achieved VR even after more than 48 weeks
of treatment, and were classified as nonresponder (NR).
In summary, among the 117 patients in whom the final
outcomes of the treatment could be evaluated, 50 patients (43%)
achieved SVR, and the remaining 67 patients, including 10 who
relapsed (9%), 31 NR (26%), and 26 withdrawals (22%), were
classified as non-SVR.
Predictors of HCV Treatment after LDLT
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Factors Predictive of Virological Response
Factors that could predict virological response were analyzed by
comparing patients in the VR (n= 77) and non-VR (n= 31) groups
(Table 1). Univariate analysis demonstrated that a low pretrans-
plant serum HCV RNA level (less than 500 kIU/mL, P,0.001;
and less than 1000 kIU/mL, P,0.001), an ABO-mismatched
donor (P=0.036), HCV genotype (non-1, P=0.001), and a low
pretreatment serum HCV RNA level (less than 5000 kIU/mL,
P=0.020) were significantly associated with VR. There were no
significant associations with any other variables, including donor
factors. Multivariate analysis revealed that the 3 variables that
retained a significant association in the model were a pretransplant
serum HCV RNA level less than 500 kIU/mL [odds ratio (OR):
0.178, 95% confidence interval (CI): 0.054–0.535, P=0.001], a
non-1 HCV genotype (OR: 0.087, 95% CI: 0.000–0.589,
P=0.008), and an ABO-mismatched donor (OR: 5.492, 95%
CI: 1.004–58.06, P=0.049) (Table 2). All 20 patients with a non-1
HCV genotype achieved VR, while VR rate in patients with the
HCV genotype 1 was 65% (57 out of 88 patients). In the patients
with HCV genotype 1, VR rate was 80% (36 of 45 patients) when
pretransplant serum HCV-RNA level was less than 500 kIU/mL
and 42% (15 of 36 patients) when it was 500 kIU/mL or more.
Among 22 recipients from ABO-mismatched donors, 20 patients
(91%) showed VR, while 57 (66%) out of 86 patients who
underwent LDLT from an ABO-matched (identical and compat-
ible) donor achieved VR.
Factors Predictive of SVR
The same variables were analyzed to clarify factors that
predicted SVR by comparing patients in the SVR (n= 50) and
non-SVR (n= 67) groups (Table 1). By univariate analysis, the
same variables that had a significant association with VR were
identified as significant predictive factors for SVR–low pretrans-
plant serum HCV RNA levels (less than 100 kIU/mL, P=0.028;
Figure 1. Flow diagram showing the outcome of interferon therapy in patients with recurrent hepatitis C after living donor liver
transplantation (LDLT) and indicating the classification of patients in this study. N, number of patients; VR, virological response; SVR,
sustained virological response; NR, nonresponder.
doi:10.1371/journal.pone.0058380.g001
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Table 1. Baseline predictive factors before liver transplantation (pre-LT), at liver transplantation (at LT), and before interferon
therapy (pre-IFN) associated with virorogical response (VR) and sustained VR (SVR): Univariate analysis.
VR non-VR P SVR non-SVR P
n=77 n=31 n=50 n=67
Age at LT (years) 55 (8267) 56 (37269) 0.462 54.5 (8267) 56 (30269) 0.212
Gender Male 45 (74%) 16 (26%) 0.518 30 (46%) 35 (54%) 0.404
Female 32 (68%) 15 (32%) 20 (38%) 32 (62%)
HCC pre-LT No 29 (71%) 12 (29%) 0.919 18 (43%) 24 (57%) 0.984
Yes 48 (72%) 19 (28%) 32 (43%) 43 (57%)
MELD pre-LT 15.5 (3251) 15 (6225) 0.403 16 (3251) 15 (0243) 0.616
Child-Pugh pre-LT A/B 35 (74%) 12 (26%) 0.488 25 (49%) 26 (51%) 0.192
C 41 (68%) 19 (32%) 24 (37%) 41 (63%)
unknown 1 0 1 0
Serum HCV RNA pre-LT ,100 kIU/mL 16 (89%) 2 (11%) 0.063 11 (65%) 6 (35%) 0.028
100 kIU/mL# 52 (65%) 28 (35%) 31 (35%) 57 (65%)
unknown 9 1 8 4
Serum HCV RNA pre-LT ,500 kIU/mL 50 (85%) 9 (15%) ,0.001 30 (55%) 25 (45%) 0.002
500 kIU/mL# 18 (46%) 21 (54%) 12 (24%) 38 (76%)
unknown 9 1 8 4
Serum HCV RNA pre-LT ,1000 kIU/mL 56 (81%) 13 (19%) ,0.001 34 (49%) 36 (51%) 0.013
1000 kIU/mL# 12 (41%) 17 (59%) 8 (23%) 27 (77%)
unknown 9 1 8 4
HCV genotype Non-1 20 (100%) 0 (0%) 0.001 15 (79%) 4 (21%) 0.002
1 57 (65%) 31 (35%) 35 (36%) 62 (64%)
unknown 0 1
Donor age at LT (years) 42 (20263) 38 (21261) 0.504 43 (20260) 38 (19263) 0.748
Donor gender at LT Male 41 (67%) 20 (33%) 0.287 27 (40%) 40 (60%) 0.538
Female 36 (77%) 11 (23%) 23 (46%) 27 (54%)
Sex mismatch Match 28 (72%) 11 (28%) 0.932 18 (43%) 24 (57%) 0.984
Mismatch 49 (71%) 20 (29%) 32 (43%) 43 (57%)
ABO mismatch Match 57 (66%) 29 (34%) 0.036 38 (40%) 56 (60%) 0.310
Mismatch 20 (91%) 2 (9%) 12 (52%) 11 (48%)
Relation of donor Nonrelated 24 (73%) 9 (27%) 0.827 16 (44%) 20 (56%) 0.803
Related 53 (71%) 22 (29%) 34 (42%) 47 (58%)
Graft type Left lobe 13 (81%) 3 (19%) 0.347 8 (62%) 5 (38%) 0.155
Right lobe 64 (70%) 28 (30%) 42 (40%) 62 (60%)
Splenectomy No 38 (68%) 18 (32%) 0.413 25 (39%) 39 (61%) 0.378
Yes 39 (75%) 13 (25%) 25 (47%) 28 (53%)
Age pre-IFN (years) 57 (15268) 57 (41270) 0.494 56 (15268) 57 (32270) 0.200
Months from LT to therapy 9.2 (1.1285.3) 8.9 (1.8259.0) 0.846 9.0 (1.3285.3) 9.0 (1.3272.4) 0.879
Trough level for tacrolimus (ng/mL)
pre-IFN
5.9 (2.0210.9) 6.4 (3.3210.6) 0.323 6.2 (2.229.5) 5.9 (2.0212.7) 0.933
MMF pre-IFN No 55 (71%) 23 (29%) 0.772 36 (43%) 48 (57%) 0.966
Yes 22 (73%) 8 (27%) 14 (42%) 19 (58%)
Prednisolone pre-IFN No 64 (70%) 28 (30%) 0.347 41 (41%) 60 (59%) 0.245
Yes 13 (81%) 3 (19%) 9 (56%) 7 (44%)
Serum HCV RNA pre-IFN ,1000 kIU/mL 17 (89%) 2 (11%) 0.064 8 (38%) 13 (62%) 0.583
1000 kIU/mL# 58 (67%) 29 (33%) 42 (45%) 52 (55%)
unknown 2 0 0 2
Serum HCV RNA pre-IFN ,5000 kIU/mL 52 (78%) 15 (22%) 0.020 36 (50%) 36 (50%) 0.030
5000 kIU/mL# 18 (55%) 15 (45%) 10 (28%) 26 (72%)
unknown 7 1 4 5
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less than 500 kIU/mL, P=0.002; and less than 1000 kIU/mL,
P=0.013), HCV genotype (non-1, P=0.002), and low pretreat-
ment serum HCV RNA levels (less than 5000 kIU/mL,
P=0.030). In addition, white cell count (P=0.049) and neutrophil
count (P=0.044) before interferon therapy were significantly
associated with SVR. Multivariate analysis showed that 2 variables
were independently associated with SVR–a non-1 HCV genotype
(OR: 0.182, 95% CI: 0.054–0.614, P=0.006), and pretransplant
serum HCV RNA levels lower than 500 kIU/mL (OR: 0.310,
95% CI: 0.130–0.742, P=0.009) (Table 3). SVR rate among
patients with a non-1 HCV genotype was 79% (15 of 19 patients)
on average, 83% (10 of 12 patients) when pretransplant serum
HCV-RNA level was less than 500 kIU/mL, and 50% (2 of 4
patients) when it was 500 kIU/mL or more. In patients with HCV
genotype 1, SVR rate was 36% (35 of 97 patients) on average,
47% (20 of 43 patients) when pretransplant serum HCV-RNA
level was less than 500 kIU/mL, and 22% (10 of 45 patients) when
it was 500 kIU/mL or more.
Amino Acid Substitutions in Core Region of HCV
To determine the viral factors that predicted VR and SVR in
patients infected with HCV genotype 1b, association of aa
substitutions at aa 70 of arginine or glutamine/histidine and aa
Table 1. Cont.
VR non-VR P SVR non-SVR P
n=77 n=31 n=50 n=67
White cell count (102/mL) 51 (132114) 49 (17298) 0.135 49 (182114) 48.5 (13299) 0.049
Neutrophil count (102/mL) 26 (8289) 22 (11258) 0.127 26 (11289) 23 (8261) 0.044
Hemoglobin (g/dL) 12.0 (9.2217.2) 12.0 (8.9217.9) 0.638 12.0 (9.4217.2) 11.8 (8.9217.9) 0.157
Platelet count (104/mL) 21.7 (4.7258.1) 15.1 (4.3240.0) 0.153 20.3 (5.0258.1) 15.8 (4.3245.8) 0.165
AST (IU/L) 78 (192352) 72 (252464) 0.677 85 (212352) 75 (242547) 0.887
ALT (IU/L) 93 (182395) 82 (212392) 0.544 106 (222395) 82 (182597) 0.251
ALP (IU/L) 461 (19921985) 433 (16822977) 0.345 470 (20421985) 470 (16822977) 0.610
g-GTP (IU/L) 118.5 (1521623) 114 (2021827) 0.856 141 (1521623) 115 (2021827) 0.356
Bilirubin (mg/dL) 0.9 (0.3211.0) 0.9 (0.3210.4) 0.827 0.9 (0.4211.0) 1.0 (0.3213.7) 0.611
Activity grade pre-IFN A1 54 (75%) 18 (25%) 0.448 35 (47%) 40 (53%) 0.517
A2 22 (65%) 12 (35%) 14 (36%) 25 (64%)
A3 1 (50%) 1 (50%) 1 (33%) 2 (67%)
Fibrosis stage pre-IFN F0 9 (60%) 6 (40%) 0.446 6 (32%) 13 (68%) 0.530
F1 54 (75%) 18 (25%) 34 (46%) 40 (54%)
F2/3 14 (67%) 7 (33%) 10 (42%) 14 (58%)
Steatosis (5%,) pre-IFN No 40 (69%) 18 (31%) 0.609 27 (42%) 38 (58%) 0.633
Yes 36 (73%) 13 (27%) 23 (46%) 27 (54%)
unknown 1 0 0 2
Cholestasis pre-IFN No 58 (71%) 24 (29%) 0.903 38 (42%) 53 (58%) 0.577
Yes 18 (72%) 7 (28%) 12 (48%) 13 (52%)
unknown 1 0 0 1
NOTE. Qualitative variables are shown in number; and quantitative variables expressed as median (range). P-values are calculated by Wald test for logistic regression
analysis.
LT, liver transplantation; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; HCV, hepatitis C virus; MMF, mycophenolate mofetil; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; g-GTP, gamma-glutamyl transpeptidase.
doi:10.1371/journal.pone.0058380.t001
Table 2. Predictive factors associated with virological response (VR): Multivariate analysis.
Odds Ratio 95% confidence intervals P-value
Serum HCV RNA pre-LT ,500 kIU/mL 1 - -
500 kIU/mL# 0.178 0.054–0.535 0.001
HCV genotype Non-1 1 - -
1 0.087 0.000–0.589 0.008
ABO mismatch Match 1 - -
Mismatch 5.492 1.004-58.06 0.049
HCV, hepatitis C virus; LT, liver transplantation.
doi:10.1371/journal.pone.0058380.t002
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91 of leucine or methionine with VR and SVR were analyzed in
40 patients, whose pre-treatment sera were stored (Table 4). As a
result, substitutions of both aa 70 and aa 91 were not significantly
associated with VR and SVR.
Predictors of Withdrawal from Therapy
Predictive factors for withdrawal from the treatment protocol
were evaluated by comparing 26 patients who withdrew from the
treatment protocol and the patients who completed the treatment
including patients with SVR, patients who relapsed, and NR.
None of the variables analyzed had a significant effect on
withdrawal (Data not shown).
Discussion
In this study, we identified 2 independent predictors of SVR in
patients with recurrent hepatitis C after LDLT by multivariate
analysis: A non-1 HCV genotype and pretransplant serum HCV-
RNA levels lower than 500 kIU/mL. The same factors were
identified as predictors for VR, which purely indicates response to
interferon therapy, by excluding the influences of the premature
termination of the therapy and virological relapse after termina-
tion of the treatment. In addition, an ABO-incompatible LDLT
was identified as an independent variable predicting VR.
In non-transplant settings, pretreatment predictors of response
to interferon therapy have been analyzed in many studies, and the
viral genotype and pretreatment viral load have been almost
invariably shown to be 2 major predictors of SVR [41,42,43,44].
SVR rates were higher in patients infected with a non-1 HCV
genotype and in those with a low pretreatment viral load. These 2
factors have been also identified in several reports [16,17,18,19] as
factors predicting SVR in patients with recurrent hepatitis C after
DDLT. In the present study, a non-1 HCV genotype was again
identified as an independent predictive factor for both VR and
SVR in patients with recurrent hepatitis C after LDLT by
multivariate analysis. A pretreatment viral load ,5000 kIU/mL
was also a significant predictive factor by univariate analysis, but it
was not an independently associated variable by multivariate
analysis. On the other hand, pretransplant viral load was identified
as an independent variable predictive of both VR and SVR by
multivariate analysis.
While reports of factors that can control viral load exist, the
mechanism by which serum HCV-RNA levels are regulated has
not yet been completely clarified. A correlation between mutations
in the ISDR sequence in the NS5A region of the HCV genome
and serum HCV RNA levels has been reported. We did not
analyze this viral factor in the current study; however, it is possible
that the HCV genome sequence determines both pretransplant
viremia and response to interferon therapy. The host polymor-
phism in IL28B, which was identified as a strong predictor of
virological response to interferon therapy in patients with hepatitis
C, was recently reported to be associated with baseline viral load
[26,45]. The allele associated with a better treatment response is
associated with a higher baseline viral load. This finding does not
correspond with our results showing that a low HCV load predicts
a better response to treatment. We speculate that the balance
between host immunity and HCV replication regulates the serum
HCV load, and that this balance also determines VR. As
pretreatment viral load in post-transplant patients is influenced
by immunosuppressive agents, the original host-virus balance
Table 4. Association of amino acid substitutions in the core region with virorogical response (VR) and sustained VR (SVR) in 40
patients infected with HCV genotype 1b: Univariate analysis.
VR non-VR P SVR non-SVR P
n=22 n=13 n=14 n=24
Core aa 70 Arg 9 (75%) 3 (25%) 0.289 7 (50%) 7 (50%) 0.204
Gln/His 13 (57%) 10 (43%) 7 (29%) 17 (71%)
Core aa 91 Leu 14 (64%) 8 (36%) 0.902 9 (38%) 15 (63%) 0.912
Met 8 (62%) 5 (38%) 5 (36%) 9 (64%)
Core aa 70 and 91 70 Arg and 91 Leu 6 (67%) 3 (33%) 0.784 5 (50%) 5 (50%) 0.320
Others 16 (62%) 10 (38%) 9 (32%) 19 (68%)
Core aa 70 and 91 70 Gln/His and 91 Met 5 (50%) 5 (50%) 0.324 3 (30%) 7 (70%) 0.603
Others 17 (68%) 8 (32%) 11 (39%) 17 (61%)
NOTE. Data are shown in number. P-values are calculated by Wald test for logistic regression analysis.
Arg, Arginine; Gln, glutamine; His, histidine; Leu, leucine; Met, methionine.
doi:10.1371/journal.pone.0058380.t004
Table 3. Predictive factors associated with sustained virological response (SVR): Multivariate analysis.
Odds Ratio 95% confidence intervals P-value
HCV genotype Non-1 1 - -
1 0.182 0.054–0.614 0.006
Serum HCV RNA pre-LT ,500 kIU/mL 1 - -
500 kIU/mL# 0.310 0.130–0.742 0.009
HCV, hepatitis C virus; LT, liver transplantation.
doi:10.1371/journal.pone.0058380.t003
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would be reflected better by serum HCV levels before transplan-
tation than by those after transplantation. It is unclear whether this
result is specific to LDLT or holds true for both DDLT and
LDLT. The significance of pretransplant viral load in DDLT as a
predictor for virological response to post-transplant interferon
therapy has not been analyzed in most previous studies [10].
Further analysis in patients who receive DDLT could help clarify
the underlying mechanism.
Liver transplantation across the ABO blood-type barrier (ABO-
incompatible) is generally contraindicated because of the possibil-
ity of graft loss caused by antibody-mediated rejection and is
performed under exceptional circumstances as a rescue option in
an emergent situation. However, ABO-incompatible LDLT has
been performed in Japan to overcome organ shortage problems.
Recently, rituximab prophylaxis and local infusion of prostaglan-
din E1 and steroids were established as therapeutic measures for
recipients who underwent ABO-incompatible LDLT, and these
treatments improved outcomes [46]. Interestingly, in this study, we
found that an ABO-mismatched donor is associated with VR to
interferon therapy. The reason for this interesting finding is
unclear, but it is possible that either subclinical antibody-mediated
rejection or drugs such as rituximab and prostaglandin E1 used in
ABO-incompatible recipients may contribute to the higher VR to
interferon therapy. There is hope that future studies to clarify the
basic mechanism underlying this result will lead to a novel strategy
to improve the efficacy of interferon therapy in patients with
hepatitis C.
Amino acid substitutions of core region of HCV were not
associated with treatment response in our analysis. We do not
know the reason for the difference of impact of substitution of core
aa 70 and aa 91 on virological response to interferon therapy from
a previous report, in which SVR rate were significantly higher in
transplant recipients with aa 70 of arginine and aa 91 of leucine of
core region of HCV [33]. As sample size of both the previous
study and our present study are small, and our present study did
not assess the other HCV RNA mutations, including ISDR [32]
and interferon/ribavirin resistance-determining region [47] in
NS5A, and IL28B polymorphism in recipients and donors, further
analysis should be required in larger cohorts.
Another aim of this study was to identify predictive variables for
adverse events during interferon therapy, but none of the studied
factors proved to be statistically significant predictors of with-
drawal from the treatment protocol. As patients withdrew from the
treatment for diverse reasons, it would be difficult to predict each
adverse event before the initiation of interferon therapy. There-
fore, careful follow-up during the treatment procedure is
important for early detection of adverse events and to prevent
progression to severe complications.
In this study, the final outcomes of the treatment including
standard interferon plus ribavirin and peginterferon plus ribavirin
were analyzed. Difference of the efficacy between standard
interferon and peginterferon might affect the results of our present
study. We predicted that patients who had virological response to
standard interferon would also show the same response to
peginterferon, because it is reported that the efficacy of
peginterferon plus ribavirin is higher than that of standard
interferon plus ribavirin [44,48]. Accordingly, the patients who
achieved SVR by standard interferon were included in the present
study. On the other hand, all nonresponders and all patients who
relapsed by standard interferon plus ribavirin were retreated with
peginterferon plus ribavirin, and we analyzed the final outcomes of
the peginterferon plus ribavirin therapy. Therefore, we conclude
that the difference of treatment regimen has little influence on our
results.
In conclusion, SVR to antiviral therapy in patients with
recurrent hepatitis C after LDLT is predictable before transplant
by serum HCV-RNA level and HCV genotype. In addition,
patients who undergo ABO-incompatible LDLT appear to have a
better VR to interferon therapy after liver transplantation.
Mechanisms underlying these interesting results are unknown at
present, but these findings are likely to be useful for improved
clinical assessment of patients with hepatitis C after liver
transplantation, and could lead to development of new strategies
for better outcomes in LDLT recipients with the HCV genotype 1
and/or a higher pretransplant viral load.
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